Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab

Cara Rosenbaum,Michaela Liedtke, Paul Christos,Hyemin Kim, Kathleen Pogonowski, Natalie Agudo, Bruna Barroso,Anthony Shelton, Samantha Reilly, Courtney Gadbois,John Mark Sloan,Vaishali Sanchorawala,Anita D'Souza

Case Medical Research（2023）

引用 0|浏览1

暂无评分

摘要

Introduction: Daratumumab (Dara) has changed the treatment paradigm in newly diagnosed and relapsed AL amyloidosis (RAL). Efficacy of Dara retreatment in RAL and Dara reexposure with (w/) effective partners such as IMiDs is unknown. We hypothesize that DPd [Dara, pomalidomide (Pom) and dexamethasone (dex)] in previously Dara exposed RAL patients (pts), including pts with low dFLC (20-50 mg/L), will yield deeper hematologic (hem) responses.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要